Drugs / ASKG712
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05940428 | Oct 2023 → Oct 2024 | diabetic macular edema | Visara, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05456828 | Feb 2023 → Nov 2025 | wet macular degeneration | Visara, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-02-15 | AffaMed Therapeutics Limited | Regulatory AffaMed Therapeutics Announces IND Clearance by US FDA for AM712 – a Novel Bispecific Biologic for the Treatment of Retinal Vascular Diseases affamed.com ↗ |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-10-27 | Jiangsu Aosaikang Pharmaceutical Co., Ltd. | Subsidiary AskGene, Reaches License Agreement for Ophthalmic Innovative Drug ASKG712 ask-pharm.com ↗ |
| 2022-02-15 | AffaMed Therapeutics Limited | AffaMed Therapeutics Announces IND Clearance by US FDA for AM712 – a Novel Bispecific Biologic for the Treatment of Retinal Vascular Diseases affamed.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASKG712 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05456828 ↗ |
| Action | Inhibit | “Ang-2 antagonist” NCT05456828 ↗ |
| Modality | Monoclonal antibody | “ASKG712 is a recombinant anti-VEGF humanized monoclonal antibody and Ang-2 antagonist peptide fusion protein” NCT05456828 ↗ |
| Route | Intravitreal | “Single or multiple ascending dose of ASKG712 by intravitreal injection” NCT05456828 ↗ |